Skip to main content

COVID-19 vaccines and the pandemic's third year

The world is still grappling with how to stay ahead of a mutating coronavirus. The vaccine focus has now shifted to sustaining longer-term efforts, and developers like Pfizer and Moderna have successfully updated their vaccines to better match circulating omicron variants.

included in this trendline
  • Pfizer, BioNTech data support new Covid booster’s advantage over original vaccine
  • Novavax details trial results for omicron-targeting booster shots
  • Moderna cuts sales forecasts for its COVID-19 vaccine
Our Trendlines go deep on the biggest trends. These special reports, produced by our team of award-winning journalists, help business leaders understand how their industries are changing.
Davide Savenije Editor-in-Chief at Industry Dive.